Consumers now expect to see ingredient lists that are transparent, understandable, and free from unnecessary fillers or artificial additives
The answer is no, according to the current evidence
Tirzepatide (Mounjaro, Zepbound) : A dual GLP-1/GIP receptor agonist approved for diabetes and weight management
Dose adjustmentssuch as reducing spironolactone dosage or increasing monitoring frequencyare common
Building on the promising Phase I clinical data generated by Eccogene, we believe this oral GLP-1RA molecule could offer alternatives to current injectable therapies both as a potential monotherapy as well as in combination for cardiometabolic diseases such as type-2 diabetes, as well as for obesity
Yagi M, Kishimura Y, Okuda F, Ogura M, Ishizaki K, Takabe W, et al